<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40511748</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Textbook Outcomes of Minimally Invasive Total Mesorectal Excision: A Composite Tool to Assess and Compare Outcomes for Benchmarking.</ArticleTitle><Pagination><StartPage>1042</StartPage><EndPage>1051</EndPage><MedlinePgn>1042-1051</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003837</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Textbook outcome is an integrated measure including both clinical and oncological outcomes. Within minimally invasive rectal cancer surgery, whether the achievement of textbook outcome translates into improved oncological outcomes is not studied.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate textbook outcome and its associated factors for patients undergoing minimally invasive total mesorectal excision.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Single-center retrospective study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The study was conducted at a high-volume tertiary referral cancer center in India.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients receiving elective laparoscopic or robotic total mesorectal excision from 2013 to 2023 were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The number of patients achieving textbook outcome, institute's time trend, factors affecting textbook outcome, and intermediate oncological outcomes were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1394 patients who underwent minimally invasive total mesorectal excision, 831 patients (60%) achieved textbook outcome. The conversion rate to open surgery is 0.2% with Clavien-Dindo grade 3 or higher complications in 1.6% of patients. Twenty-seven percent of patients had a prolonged hospital stay, with a 30-day readmission rate being 3%. Four percent of patients had a poor lymph node yield, the R0 resection rate was 98%, and adjuvant therapy delay was observed in 6% of patients. The achievement of textbook outcome resulted in improved 3-year overall survival (92.1% vs 83.7%, p &lt; 0.001) and disease-free survival (81.5% vs 75.7%, p = 0.007).</AbstractText><AbstractText Label="LIMITATION" NlmCategory="CONCLUSIONS">The results of our study cannot be generalized to open total mesorectal excision, beyond total mesorectal excision and extended total mesorectal excision, where benchmark criteria definitions vary.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Textbook outcome for minimally invasive total mesorectal excision was achieved in 60% of patients with rectal cancer at a high-volume tertiary cancer institute. It could be used for benchmarking, thus improving the results of minimally invasive total mesorectal excision, and as a quality indicator in nationwide surgical audits. See Video Abstract .</AbstractText><AbstractText Label="RESULTADOS TPICOS DE LA ESCISIN MESORRECTAL TOTAL MNIMAMENTE INVASIVA UNA HERRAMIENTA COMPUESTA PARA EVALUAR Y COMPARAR RESULTADOS O ESTABLECER PUNTOS DE REFERENCIA" NlmCategory="UNASSIGNED">ANTECEDENTES:El resultado te&#xf3;rico es una medida integrada que incluye tanto los resultados cl&#xed;nicos como los oncol&#xf3;gicos. En el &#xe1;mbito de la cirug&#xed;a m&#xed;nimamente invasiva del c&#xe1;ncer rectal, no se ha estudiado si la consecuci&#xf3;n del resultado te&#xf3;rico se traduce en una mejora de los resultados oncol&#xf3;gicos.OBJETIVO:Evaluar el resultado te&#xf3;rico y sus factores asociados en pacientes sometidos a disecci&#xf3;n mesorrectal total m&#xed;nimamente invasiva.DISE&#xd1;O:Estudio retrospectivo en un &#xfa;nico centro.ENTORNO:El estudio se llev&#xf3; a cabo en un centro oncol&#xf3;gico terciario de referencia con un gran volumen de pacientes en la India.PACIENTES:Se incluyeron todos los pacientes sometidos a una extirpaci&#xf3;n mesorrectal total laparosc&#xf3;pica o rob&#xf3;tica electiva entre 2013 y 2023.PRINCIPALES MEDIDAS DE RESULTADO:Se evaluaron el n&#xfa;mero de pacientes que alcanzaron el resultado te&#xf3;rico, la tendencia temporal del instituto, los factores que influyeron en el resultado te&#xf3;rico y los resultados oncol&#xf3;gicos intermedios.RESULTADOS:De los 1394 pacientes que se sometieron a una extirpaci&#xf3;n mesorrectal total m&#xed;nimamente invasiva, 831 (60 %) lograron el resultado te&#xf3;rico. La tasa de conversi&#xf3;n a cirug&#xed;a abierta es del 0,2 %, con complicaciones &#x2265; Clavien-Dindo 3 en el 1,6 % de los pacientes. El 27 % de los pacientes tuvieron una estancia hospitalaria prolongada, con una tasa de reingreso a los 30 d&#xed;as del 3 %. El 4 % de los pacientes present&#xf3; un rendimiento linfonodal deficiente, la tasa de resecci&#xf3;n R0 fue del 98 % y se observ&#xf3; un retraso en la terapia adyuvante en el 6 % de los pacientes. El logro de los resultados te&#xf3;ricos dio lugar a una mejora de la supervivencia global a 3 a&#xf1;os (92,1 % frente a 83,7 %, p &lt;0,001) y de la supervivencia libre de enfermedad (81,5 % frente a 75,7 %, p = 0,007).LIMITACIONES:Los resultados de nuestro estudio no pueden generalizarse a la disecci&#xf3;n mesorrectal total abierta, m&#xe1;s all&#xe1; de la disecci&#xf3;n mesorrectal total y la disecci&#xf3;n mesorrectal total ampliada, donde var&#xed;an las definiciones de los criterios de referencia.CONCLUSI&#xd3;N:Se obtuvieron resultados de libro de texto para la extirpaci&#xf3;n mesorrectal total m&#xed;nimamente invasiva en el 60 % de los pacientes con c&#xe1;ncer rectal en un instituto oncol&#xf3;gico terciario de alto volumen. Podr&#xed;a utilizarse como referencia, mejorando as&#xed; los resultados de la extirpaci&#xf3;n mesorrectal total m&#xed;nimamente invasiva y tambi&#xe9;n como indicador de calidad en auditor&#xed;as quir&#xfa;rgicas a nivel nacional. (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Vipul</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Colorectal Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mor</LastName><ForeName>Akash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Colorectal Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mundhada</LastName><ForeName>Rohit O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Division of Colorectal Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazi</LastName><ForeName>Mufaddal K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Colorectal Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daphal</LastName><ForeName>Anjali Jalindar</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Research Secretariat, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Ankit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Colorectal Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desouza</LastName><ForeName>Ashwin L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Colorectal Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saklani</LastName><ForeName>Avanish P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Division of Colorectal Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019985" MajorTopicYN="Y">Benchmarking</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="Y">Robotic Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="N">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Minimally invasive</Keyword><Keyword MajorTopicYN="N">Rectal cancer</Keyword><Keyword MajorTopicYN="N">Textbook outcomes</Keyword><Keyword MajorTopicYN="N">Total mesorectal excision</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>7</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40511748</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003837</ArticleId><ArticleId IdType="pii">00003453-990000000-00978</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kolfschoten NE, Kievit J, Gooiker GA, et al. Focusing on desired outcomes of care after colon cancer resections; hospital variations in textbook outcome. Eur J Surg Oncol. 2013;39:156&#x2013;163.</Citation></Reference><Reference><Citation>Sun Y, Jiang W, Tang Z, Wang X, Huang Y, Chi P. Textbook outcome in low rectal cancer after neoadjuvant chemoradiotherapy: post hoc analysis of the LASRE randomized clinical trial. Eur J Surg Oncol. 2024;50:108519.</Citation></Reference><Reference><Citation>Beyond TME. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013;100:1009&#x2013;1014.</Citation></Reference><Reference><Citation>Saravanabavan S, Kazi M, Murugan J, et al. Outcomes of extended total mesorectal excision in patients with locally advanced rectal cancer. Colorectal Dis. 2023;25:1423&#x2013;1432.</Citation></Reference><Reference><Citation>Warps AK, Detering R, Tollenaar RAEM, Tanis PJ, Dekker JWT; Dutch ColoRectal Audit group. Textbook outcome after rectal cancer surgery as a composite measure for quality of care: a population-based study. Europ J Surg Oncol. 2021;47:2821&#x2013;2829.</Citation></Reference><Reference><Citation>Kryzauskas M, Bausys A, Abeciunas V, et al. Achieving textbook outcomes in colorectal cancer surgery is associated with improved long-term survival: results of the multicenter prospective cohort study. J Clin Med. 2024;13:1304.</Citation></Reference><Reference><Citation>Azevedo JM, Panteleimonitis S, Mi&#x161;kovi&#x107; D, et al. Textbook oncological outcomes for robotic colorectal cancer resections: an observational study of five robotic colorectal units. Cancers (Basel). 2023;15:3760.</Citation></Reference><Reference><Citation>Yang C-C, Tian Y-F, Liu W-S, et al. The association between the composite quality measure &#x201c;textbook outcome&#x201d; and long term survival in operated colon cancer. Medicine (Baltimore). 2020;99:e22447.</Citation></Reference><Reference><Citation>Han J, Noh GT, Yeo SA, et al. The number of retrieved lymph nodes needed for accurate staging differs based on the presence of preoperative chemoradiation for rectal cancer. Medicine (Baltimore). 2016;95:e4891.</Citation></Reference><Reference><Citation>G&#xf6;genur M, Rosen AW, Iveson T, et al. time from colorectal cancer surgery to adjuvant chemotherapy: post hoc analysis of the SCOT randomized clinical trial. JAMA Surg. 2024;159:865&#x2013;871.</Citation></Reference><Reference><Citation>Mehta R, Tsilimigras DI, Paredes AZ, et al. Is patient satisfaction dictated by quality of care among patients undergoing complex surgical procedures for a malignant indication? Ann Surg Oncol. 2020;27:3126&#x2013;3135.</Citation></Reference><Reference><Citation>Mehta R, Tsilimigras DI, Paredes AZ, et al. Comparing textbook outcomes among patients undergoing surgery for cancer at U. S. News &amp; World Report ranked hospitals. J Surg Oncol. 2020;121:927&#x2013;935.</Citation></Reference><Reference><Citation>Busweiler LAD, Schouwenburg MG, van Berge Henegouwen MI, et al. Textbook outcome as a composite measure in oesophagogastric cancer surgery. Br J Surg. 2017;104:742&#x2013;750.</Citation></Reference><Reference><Citation>Merath K, Chen Q, Bagante F, et al. Textbook outcomes among Medicare patients undergoing hepatopancreatic surgery. Ann Surg. 2020;271:1116&#x2013;1123.</Citation></Reference><Reference><Citation>Van Der Werf LR, Wijnhoven BPL, Fransen LFC, et al. A national cohort study evaluating the association between short-term outcomes and long-term survival after esophageal and gastric cancer surgery. Ann Surg. 2019;270:868&#x2013;876.</Citation></Reference><Reference><Citation>Barclay M, Dixon-Woods M, Lyratzopoulos G. The problem with composite indicators. BMJ Qual Saf. 2019;28:338&#x2013;344.</Citation></Reference><Reference><Citation>Fukuoka A, Makizumi R, Asano T, Hamabe T, Otsubo T. surgical outcomes of colorectal cancer surgery for &#x2265; 85-year-old patients in our hospital: retrospective comparison of short- and long-term outcomes with younger patients. J Anus Rectum Colon. 2021;5:247&#x2013;253.</Citation></Reference><Reference><Citation>Taffurelli G, Montroni I, Ghignone F, et al. Frailty assessment can predict textbook outcomes in senior adults after minimally invasive colorectal cancer surgery. Europ J Surg Oncol. 2023;49:626&#x2013;632.</Citation></Reference><Reference><Citation>Patil PS, Saklani A, Gambhire P, et al. Colorectal cancer in India: an audit from a tertiary center in a low prevalence area. Indian J Surg Oncol. 2017;8:484&#x2013;490.</Citation></Reference><Reference><Citation>Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19:2212&#x2013;2223.</Citation></Reference><Reference><Citation>Kalagara R, Norain A, Chang Y-H, Stucky C-C, Wasif N. Association of textbook outcome and surgical case volume with long-term survival in patients undergoing surgical resection for pancreatic cancer. J Am Coll Surg. 2022;235:829&#x2013;837.</Citation></Reference><Reference><Citation>Mehta R, Paredes AZ, Tsilimigras DI, et al. Influence of hospital teaching status on the chance to achieve a textbook outcome after hepatopancreatic surgery for cancer among Medicare beneficiaries. Surgery. 2020;168:92&#x2013;100.</Citation></Reference><Reference><Citation>Khalil M, Tsilimigras DI, Endo Y, et al. Association of textbook outcome and hospital volume with long-term survival following resection for hepatocellular carcinoma: what matters more? J Gastrointest Surg. 2023;27:2763&#x2013;2770.</Citation></Reference><Reference><Citation>Levy J, Gupta V, Amirazodi E, et al.; PRESTO Group. Gastrectomy case volume and textbook outcome: an analysis of the Population Registry of Esophageal and Stomach Tumours of Ontario (PRESTO). Gastric Cancer. 2020;23:391&#x2013;402.</Citation></Reference><Reference><Citation>Russolillo N, Gentile V, Ratti F, et al. Incidence and predictors of textbook outcome after simultaneous liver and rectal surgeries for Stage IV rectal cancer. Colorectal Dis. 2022;24:50&#x2013;58.</Citation></Reference><Reference><Citation>Tsilimigras DI, Mehta R, Merath K, et al. Hospital variation in textbook outcomes following curative-intent resection of hepatocellular carcinoma: an international multi-institutional analysis. HPB (Oxford). 2020;22:1305&#x2013;1313.</Citation></Reference><Reference><Citation>Kulshrestha S, Bunn C, Patel PM, et al. Textbook oncologic outcome is associated with increased overall survival after esophagectomy. Surgery. 2020;168:953&#x2013;961.</Citation></Reference><Reference><Citation>van der Kaaij RT, de Rooij MV, van Coevorden F, et al. Using textbook outcome as a measure of quality of care in oesophagogastric cancer surgery. Br J Surg. 2018;105:561&#x2013;569.</Citation></Reference><Reference><Citation>Sweigert PJ, Eguia E, Baker MS, et al. Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol. 2020;121:936&#x2013;944.</Citation></Reference><Reference><Citation>Brown KGM, Solomon MJ, Koh CE, et al. Defining benchmarks for pelvic exenteration surgery: a multicentre analysis of patients with locally advanced and recurrent rectal cancer [Epub ahead or print]. Ann Surg. 2024. doi:10.1097/SLA.0000000000006348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000006348</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40331664</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Oncological Outcomes of Intersphincteric Resection Versus Abdominoperineal Resection for ypT3 Low Rectal Cancer After Neoadjuvant Chemoradiotherapy: A Multicenter Retrospective Analysis.</ArticleTitle><Pagination><StartPage>951</StartPage><EndPage>961</EndPage><MedlinePgn>951-961</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003821</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sphincter preservation, crucial for patients traditionally facing abdominoperineal resection, was advanced by neoadjuvant chemoradiotherapy and intersphincteric resection. T4 lower rectal cancer with levator ani muscle infiltration was a contraindication for intersphincteric resection, with most debates on intersphincteric resection indications focusing on the T3 stage.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate oncological outcomes in patients with locally advanced distal rectal cancer, located within 5&#x2009;cm from the anal verge, who underwent preoperative chemoradiotherapy followed by intersphincteric resection or abdominoperineal resection, with a focus on ypT3 very low rectal cancers that were technically feasible for intersphincteric resection without evidence of levator ani or external sphincter muscle invasion intraoperatively.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A retrospective analysis of prospectively collected data.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Conducted at 2 colorectal surgery referral centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">The study included 381 patients with ypT3 low rectal cancer who underwent chemoradiotherapy between 2010 and 2021.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The main outcome measures were 5-year disease-free survival, 5-year overall survival, circumferential resection margin status, and complications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 5-year disease-free survival rates were 63.4% for intersphincteric resection and 63.8% for abdominoperineal resection ( p = 0.806), with 5-year overall survival rates at 78.8% for intersphincteric resection and 67.5% for abdominoperineal resection ( p = 0.103). There were no significant differences in 5-year local recurrence or metastasis rates. Circumferential resection margin involvement was low in both groups: 1.9% (5/258) for intersphincteric resection and 4.9% (6/123) for abdominoperineal resection ( p = 0.202). Distal margin involvement was minimal in intersphincteric resection at 0.8% (2/258). Abdominoperineal resection had higher wound infection rates at 15.4% compared to 0.7% in intersphincteric resection ( p &lt; 0.001) and a longer median postoperative hospital stay (10.0 vs 7.0 days for intersphincteric resection, p &lt; 0.001). In abdominoperineal resection cases, primary closure was used for reconstruction, with pelvic peritoneum closure in 4 instances. No significant difference in perineal wound infection rates was observed between those with and without pelvic peritoneum closure ( p = 0.495). Subgroup analysis of intersphincteric resection with handsewn anastomoses showed no significant differences in 5-year disease-free survival (53.8% vs 63.8%, p = 0.068), overall survival (74.5% vs 67.5%, p = 0.313), or local recurrence rates (20.2% vs 21.7%, p = 0.877) compared to abdominoperineal resection.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The retrospective design introduced potential selection bias. Procedures were conducted by highly skilled surgeons, which may limit the generalizability of the findings. The study lacked assessment of certain oncological surgical quality control indicators and long-term functional outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For patients with ypT3 low rectal cancer after chemoradiotherapy, intersphincteric resection is safe and oncologically comparable to abdominoperineal resection when negative margins can be achieved. See Video Abstract.</AbstractText><AbstractText Label="RESULTADOS ONCOLGICOS DE LA RESECCIN INTERSFINTERIANA FRENTE A LA RESECCIN ABDOMINOPERINEAL EN EL CNCER RECTAL BAJO YPT TRAS LA QUIMIORRADIOTERAPIA NEOADYUVANTE ANLISIS RETROSPECTIVO MULTICNTRICO" NlmCategory="UNASSIGNED">ANTECEDENTES:La preservaci&#xf3;n del esf&#xed;nter, crucial para los pacientes que tradicionalmente se enfrentan a una resecci&#xf3;n abdominoperineal, ha sido impulsado gracias a la quimiorradioterapia neoadyuvante y la resecci&#xf3;n intersfinteriana. El c&#xe1;ncer rectal inferior T4 con infiltraci&#xf3;n del m&#xfa;sculo elevador del ano ha sido una contraindicaci&#xf3;n para la resecci&#xf3;n intersfinteriana, y la mayor&#xed;a de los debates se centran sobre las indicaciones de la resecci&#xf3;n intersfinteriana en el estadio T3.OBJETIVO:Evaluar los resultados oncol&#xf3;gicos en pacientes con c&#xe1;ncer rectal distal localmente avanzado, localizados a menos de 5&#x2009;cm del borde anal, que se sometidos a quimiorradioterapia preoperatoria seguida de resecci&#xf3;n intersfinteriana o resecci&#xf3;n abdominoperineal, centr&#xe1;ndose en los c&#xe1;nceres rectales muy bajos ypT3 que eran t&#xe9;cnicamente viables para la resecci&#xf3;n intersfinteriana sin evidencia de invasi&#xf3;n del m&#xfa;sculo elevador del ano o del esf&#xed;nter externo durante la intervenci&#xf3;n quir&#xfa;rgica.DISE&#xd1;O:An&#xe1;lisis retrospectivo de datos recogidos prospectivamente.ENTORNO:Realizado en dos centros de referencia en cirug&#xed;a colorrectal.PACIENTES:El estudio incluy&#xf3; a 381 pacientes con c&#xe1;ncer rectal bajo ypT3 tras quimiorradioterapia, entre los a&#xf1;os 2010 y 2021.PRINCIPALES MEDIDAS DE RESULTADO:Supervivencia libre de enfermedad a cinco a&#xf1;os, supervivencia global a cinco a&#xf1;os, estado del margen de resecci&#xf3;n circunferencial y complicaciones.RESULTADOS:Las tasas de supervivencia libre de enfermedad a 5 a&#xf1;os fueron del 63,4 % para la resecci&#xf3;n intersfinteriana y del 63,8 % para la resecci&#xf3;n abdominoperineal ( p = 0,806), con tasas de supervivencia global a 5 a&#xf1;os del 78,8 % para la resecci&#xf3;n intersfinteriana y del 67,5 % para la resecci&#xf3;n abdominoperineal ( p = 0,103). No hubo diferencias significativas en las tasas de recurrencia local o met&#xe1;stasis a los 5 a&#xf1;os. La afectaci&#xf3;n del margen de resecci&#xf3;n circunferencial fue baja en ambos grupos: 1,9 % (5/258) para la resecci&#xf3;n intersfinteriana y 4,9 % (6/123) para la resecci&#xf3;n abdominoperineal ( p = 0,202). La afectaci&#xf3;n del margen distal fue m&#xed;nima en la resecci&#xf3;n intersfinteriana, con un 0,8 % (2/258). La resecci&#xf3;n abdominoperineal present&#xf3; tasas m&#xe1;s elevadas de infecci&#xf3;n de la herida con un 15,4 %, en comparaci&#xf3;n con el 0,7 % en la resecci&#xf3;n intersfinteriana ( p &lt; 0,001), asi como una mediana de estancia hospitalaria postoperatoria m&#xe1;s prolongada (10,0 d&#xed;as frente a 7,0 d&#xed;as para la resecci&#xf3;n intersfinteriana, p &lt; 0,001). En los casos de resecci&#xf3;n abdominoperineal, se utiliz&#xf3; el cierre primario para la reconstrucci&#xf3;n, con cierre del peritoneo p&#xe9;lvico en 4 casos. No se observaron diferencias significativas en las tasas de infecci&#xf3;n de la herida perineal entre los pacientes con y sin cierre del peritoneo p&#xe9;lvico ( p = 0,495). El an&#xe1;lisis de subgrupos de la resecci&#xf3;n intersfinteriana con anastomosis hechas con suturas a mano no mostraron diferencias significativas en la supervivencia libre de enfermedad a 5 a&#xf1;os (53,8 % frente a 63,8 %, p = 0,068), la supervivencia global (74,5 % frente a 67,5 %, p = 0,313) o las tasas de recidiva local (20,2 % frente a 21,7 %, p = 0,877) en comparaci&#xf3;n con la resecci&#xf3;n abdominoperineal.LIMITACIONES:El dise&#xf1;o retrospectivo introdujo un posible sesgo de selecci&#xf3;n. Las intervenciones fueron realizadas por cirujanos altamente cualificados, lo que puede limitar la generalizaci&#xf3;n de los resultados. El estudio no evalu&#xf3; determinados indicadores de control de calidad quir&#xfa;rgica oncol&#xf3;gica ni los resultados funcionales a largo plazo.CONCLUSIONES:En pacientes con c&#xe1;ncer rectal bajo ypT3 tras quimiorradioterapia, la ISR es segura y oncol&#xf3;gicamente comparable a la resecci&#xf3;n abdominoperineal cuando se pueden lograr m&#xe1;rgenes negativos. (Traducci&#xf3;n-Dr Osvaldo Gauto).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaojie</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Union Hospital, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yingru</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hernia and Abdominal Wall Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Wenchang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hernia and Abdominal Wall Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Lishuo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Shaoyong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hernia and Abdominal Wall Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Union Hospital, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hernia and Abdominal Wall Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Pan</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0004-1174</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Union Hospital, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>(2020B1111170004)</GrantID><Agency>the program of Guangdong Provincial Clinical Research Center for Digestive Diseases</Agency><Country/></Grant><Grant><GrantID>(81973858, 82172790)</GrantID><Agency>the National Nature Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>(2019A1515011200)</GrantID><Agency>the Natural Science Foundation of Guangdong Province</Agency><Country/></Grant><Grant><GrantID>(20191401, 20211086, 20221094)</GrantID><Agency>the Administration of Traditional Chinese Medicine of Guangdong Province</Agency><Country/></Grant><Grant><GrantID>(A2021061)</GrantID><Agency>the Medical Science and Technology Research Foundation of Guangdong Province</Agency><Country/></Grant><Grant><GrantID>(2023A04J1816)</GrantID><Agency>the Science and Technology Planning Project of Guangzhou</Agency><Country/></Grant><Grant><GrantID>(2024Y9261)</GrantID><Agency>Joint Funds for the innovation of Science and Technology, Fujian province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001003" MajorTopicYN="Y">Anal Canal</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072662" MajorTopicYN="N">Margins of Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059186" MajorTopicYN="N">Chemoradiotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominoperineal resection</Keyword><Keyword MajorTopicYN="N">Intersphincteric resection</Keyword><Keyword MajorTopicYN="N">Neoadjuvant chemoradiotherapy</Keyword><Keyword MajorTopicYN="N">ypT3 low rectal cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>7</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40331664</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003821</ArticleId><ArticleId IdType="pii">00003453-202508000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133:894&#x2013;899.</Citation></Reference><Reference><Citation>Ueno H, Mochizuki H, Hashiguchi Y, et al. Preoperative parameters expanding the indication of sphincter preserving surgery in patients with advanced low rectal cancer. Ann Surg. 2004;239:34&#x2013;42.</Citation></Reference><Reference><Citation>Ito M. ISR for T1-2 low rectal cancer: a Japanese approach. Clin Colon Rectal Surg. 2020;33:361&#x2013;365.</Citation></Reference><Reference><Citation>Abdel-Gawad W, Zaghloul A, Fakhr I, et al. Evaluation of the frequency and pattern of local recurrence following intersphincteric resection for ultra-low rectal cancer. J Egypt Natl Canc Inst. 2014;26:87&#x2013;92.</Citation></Reference><Reference><Citation>Tsukamoto S, Kanemitsu Y, Shida D, Ochiai H, Mazaki J. Comparison of the clinical results of abdominoperanal intersphincteric resection and abdominoperineal resection for lower rectal cancer. Int J Colorectal Dis. 2017;32:683&#x2013;689.</Citation></Reference><Reference><Citation>Yamada K, Saiki Y, Takano S, et al. Long-term results of intersphincteric resection for low rectal cancer in Japan. Surg Today. 2019;49:275&#x2013;285.</Citation></Reference><Reference><Citation>Weiser MR, Quah HM, Shia J, et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg. 2009;249:236&#x2013;242.</Citation></Reference><Reference><Citation>Feferman Y, Verheij FS, Williams H, et al. Outcomes of distal rectal cancer patients who did not qualify for watch-and-wait: comparison of intersphincteric resection versus abdominoperineal resection. Ann Surg Oncol. 2025;32:128&#x2013;136.</Citation></Reference><Reference><Citation>Rullier E, Goffre B, Bonnel C, Zerbib F, Caudry M, Saric J. Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum. Ann Surg. 2001;234:633&#x2013;640.</Citation></Reference><Reference><Citation>Chinese Society of Colorectal Surgery. Chinese expert consensus on intersphincteric resection for low rectal cancer (2023 edition). Zhonghua Wei Chang Wai Ke Za Zhi. 2023;26:536&#x2013;547.</Citation></Reference><Reference><Citation>Chi P, Huang SH, Lin HM, et al. Laparoscopic transabdominal approach partial intersphincteric resection for low rectal cancer: surgical feasibility and intermediate-term outcome. Ann Surg Oncol. 2015;22:944&#x2013;951.</Citation></Reference><Reference><Citation>Kim JC, Lee JL, Alotaibi AM, Yoon YS, Kim CW, Park IJ. Robot-assisted intersphincteric resection facilitates an efficient sphincter-saving in patients with low rectal cancer. Int J Colorectal Dis. 2017;32:1137&#x2013;1145.</Citation></Reference><Reference><Citation>Kim JC, Lee JL, Bong JW, et al. Oncological and anorectal functional outcomes of robot-assisted intersphincteric resection in lower rectal cancer, particularly the extent of sphincter resection and sphincter saving. Surg Endosc. 2020;34:2082&#x2013;2094.</Citation></Reference><Reference><Citation>Kim JC, Lee JL, Kim CW, Kim JR, Kim J, Park SH. Technical, functional, and oncological validity of robot-assisted total-intersphincteric resection (T-ISR) for lower rectal cancer. Eur J Surg Oncol. 2023;49:188&#x2013;195.</Citation></Reference><Reference><Citation>Wrenn SM, Cepeda-Benito A, Ramos-Valadez DI, Cataldo PA. Patient perceptions and quality of life after colon and rectal surgery: what do patients really want? Dis Colon Rectum. 2018;61:971&#x2013;978.</Citation></Reference><Reference><Citation>Kang SB, Cho JR, Jeong SY, et al.; Seoul Colorectal Research Group (SECOG). Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): a long-term prospective, multicentre, cohort study. Lancet Reg Health West Pac. 2020;6:100087.</Citation></Reference><Reference><Citation>Bossema E, Stiggelbout A, Baas-Thijssen M, van de Velde C, Marijnen C. Patients&#x2019; preferences for low rectal cancer surgery. Eur J Surg Oncol. 2008;34:42&#x2013;48.</Citation></Reference><Reference><Citation>Wang X, Jiang W, Deng Y, et al. Unraveling variations and enhancing prediction of successful sphincter-preserving resection for low rectal cancer: a post hoc analysis of the multicentre LASRE randomized clinical trial. Int J Surg. 2024;110:4031&#x2013;4042.</Citation></Reference><Reference><Citation>Shin JK, Kim HC, Lee WY, et al. Sphincter-saving surgery versus abdominoperineal resection in low rectal cancer following neoadjuvant treatment with propensity score analysis. Surg Endosc. 2022;36:2623&#x2013;2630.</Citation></Reference><Reference><Citation>Piozzi GN, Khobragade K, Aliyev V, et al. International Standardization and Optimization Group for Intersphincteric Resection (ISOG-ISR): modified Delphi consensus on anatomy, definition, indication, surgical technique, specimen description and functional outcome. Colorectal Dis. 2023;25:1896&#x2013;1909.</Citation></Reference><Reference><Citation>Deidda S, Elmore U, Rosati R, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative chemoradiation. JAMA Surg. 2021;156:1141&#x2013;1149.</Citation></Reference><Reference><Citation>Cheong C, Kim NW, Shim SR, Kang J. Evaluating the impact of induction and consolidation total neoadjuvant therapies compared to conventional chemoradiotherapy for locally advanced rectal cancer: a systematic review and network meta-analysis. Dis Colon Rectum. 2025;68:687&#x2013;701.</Citation></Reference><Reference><Citation>Kim JC, Kim CW, Lee JL, et al. Complete intersphincteric longitudinal muscle excision may be key to reducing local recurrence during intersphincteric resection. Eur J Surg Oncol. 2021;47:1629&#x2013;1636.</Citation></Reference><Reference><Citation>Kim HS, Ko S, Oh NG. Long-term results of extended intersphincteric resection for very low rectal cancer: a retrospective study. BMC Surg. 2016;16:21.</Citation></Reference><Reference><Citation>Wang XT, Li DG, Li L, Kong FB, Pang LM, Mai W. Meta-analysis of oncological outcome after abdominoperineal resection or low anterior resection for lower rectal cancer. Pathol Oncol Res. 2015;21:19&#x2013;27.</Citation></Reference><Reference><Citation>Jayne D, Pigazzi A, Marshall H, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017;318:1569&#x2013;1580.</Citation></Reference><Reference><Citation>Veenhof AA, Engel AF, van der Peet DL, et al. Technical difficulty grade score for the laparoscopic approach of rectal cancer: a single institution pilot study. Int J Colorectal Dis. 2008;23:469&#x2013;475.</Citation></Reference><Reference><Citation>Ellis CT, Maykel JA. Defining anastomotic leak and the clinical relevance of leaks. Clin Colon Rectal Surg. 2021;34:359&#x2013;365.</Citation></Reference><Reference><Citation>Cai M, He H, Hong S, Weng J. Synergistic diagnostic value of circulating tumor cells and tumor markers CEA/CA19-9 in colorectal cancer. Scand J Gastroenterol. 2023;58:54&#x2013;60.</Citation></Reference><Reference><Citation>Huang S, Huang Y, Chi P, et al. Completely abdominal approach laparoscopic partial intersphincteric resection after neoadjuvant chemoradiation for initial cT3 juxta-anal rectal cancer. J Laparoendosc Adv Surg Tech A. 2019;29:809&#x2013;816.</Citation></Reference><Reference><Citation>Wang X, Wang H, He H, et al. Clinicopathological and prognostic features of colorectal mucinous adenocarcinomas: a systematic review and meta-analysis. BMC Cancer. 2024;24:1161.</Citation></Reference><Reference><Citation>Kaya T, Dursun A. Can lymphovascular and perineural invasion be additional staging criteria in colorectal cancer? J Coll Physicians Surg Pak. 2021;31:657&#x2013;662.</Citation></Reference><Reference><Citation>Jiang W, Xu J, Cui M, et al.; LASRE trial investigators. Laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): 3-year survival outcomes of a multicentre, randomised, controlled, non-inferiority trial. Lancet Gastroenterol Hepatol. 2025;10:34&#x2013;43.</Citation></Reference><Reference><Citation>Ding P, Liska D, Tang P, et al. Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study. Ann Surg. 2012;256:111&#x2013;116.</Citation></Reference><Reference><Citation>Hudson D, Entriken F, Hodder R, Warner M. Functional outcomes and local control are acceptable following hand-sewn colo-anal anastomoses for rectal cancer: results of long-term follow-up. ANZ J Surg. 2022;92:390&#x2013;396.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38408876</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Outcomes Following Pelvic Exenteration for Locally Recurrent Rectal Cancer With and Without En Bloc Sacrectomy.</ArticleTitle><Pagination><StartPage>796</StartPage><EndPage>804</EndPage><MedlinePgn>796-804</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003154</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Extended radical resection is often the only chance of cure for locally recurrent rectal cancer. Recurrence in the posterior compartment often necessitates en bloc sacrectomy as part of pelvic exenteration to obtain clear resection margins and provide survival benefit.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare oncological outcomes, morbidity, and quality-of-life outcomes following pelvic exenteration with and without en bloc sacrectomy for recurrent rectal cancer.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Comparative cohort study with retrospective analysis of prospectively collected data.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">This study was conducted at a high-volume pelvic exenteration center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients who underwent pelvic exenteration for locally recurrent rectal cancer between 1994 and 2022.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Overall survival, postoperative morbidity, R0 resection margin, and quality-of-life outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 965 patients, 305 (31.6%) underwent pelvic exenteration for locally recurrent rectal cancer. Among these patients, 64.3% were men and the median age was 62 years (range, 29-86). One hundred eighty-five patients (60.7%) underwent en bloc sacrectomy, 65 (35.1%) underwent high transection, and 119 (64.3%) had sacrectomy below S2. R0 resection was achieved in 80% of patients with sacrectomy and 72.5% of patients without sacrectomy. Sacrectomy patients experienced more postoperative complications without increased mortality. The median overall survival was 52 months; median survival was 47 months with sacrectomy and 73 months without ( p &#x2009;=&#x2009;0.059). Quality-of-life scores were not significantly different across physical component ( p &#x2009;=&#x2009;0.346), mental component ( p &#x2009;=&#x2009;0.787), or Functional Assessment of Cancer Therapy-Colorectal ( p &#x2009;=&#x2009;0.679) scores at 24-month follow-up.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The generalizability of these findings may be limited outside of subspecialist exenteration units. Selection bias exists in a retrospective analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients undergoing pelvic exenteration with and without en bloc sacrectomy for locally recurrent rectal cancer experience similar rates of R0 resection, survival, and quality-of-life outcomes. As R0 remains the most important predictor of survival, the requirement of sacral resection should prompt referral to a subspecialist center that performs sacrectomy routinely. See Video Abstract .</AbstractText><AbstractText Label="RESULTADOS DESPUS DE LA EXENTERACIN PLVICA PARA EL CNCER DE RECTO CON RECURRENCIA LOCAL, CON Y SIN SACRECTOMA EN BLOQUE" NlmCategory="UNASSIGNED">ANTECEDENTES:La resecci&#xf3;n radical ampliada es generalmente la &#xfa;nica posibilidad de curaci&#xf3;n para el c&#xe1;ncer de recto con recurrencia local. La recurrencia en el compartimento posterior generalmente requiere sacrectom&#xed;a en bloque como parte de la exenteraci&#xf3;n p&#xe9;lvica para obtener m&#xe1;rgenes de resecci&#xf3;n claros y proporcionar un beneficio de supervivencia.OBJETIVO:Comparar los resultados oncol&#xf3;gicos, de morbilidad y de calidad de vida despu&#xe9;s de la exenteraci&#xf3;n p&#xe9;lvica con y sin sacrectom&#xed;a en bloque para el c&#xe1;ncer de recto recurrente.DISE&#xd1;O:Estudio de cohorte comparativo con an&#xe1;lisis retrospectivo de datos recopilados prospectivamente.AMBIENTE AJUSTE:Estudio realizado en un centro de exenteraci&#xf3;n p&#xe9;lvica de alto volumen.PACIENTES:Aquellos sometidos a exenteraci&#xf3;n p&#xe9;lvica por c&#xe1;ncer de recto con recurrencia local entre 1994 y 2022.PRINCIPALES MEDIDAS DE RESULTADO:Supervivencia general, morbilidad posoperatoria, margen de resecci&#xf3;n R0 y resultados de calidad de vida.RESULTADOS:305 (31,6%) de 965 pacientes se sometieron a exenteraci&#xf3;n p&#xe9;lvica por c&#xe1;ncer de recto con recurrencia local. El 64,3% de los pacientes eran hombres con una mediana de edad de 62 a&#xf1;os (rango 29-86). 185 pacientes (60,7%) fueron sometidos a sacrectom&#xed;a en bloque, 65 (35,1%) fueron sometidos a transecci&#xf3;n alta, 119 (64,3%) tuvieron sacrectom&#xed;a por debajo de S2. La resecci&#xf3;n R0 se logr&#xf3; en el 80% de los pacientes con sacrectom&#xed;a y en el 72,5% sin ella. Los pacientes de sacrectom&#xed;a experimentaron m&#xe1;s complicaciones postoperatorias sin aumento de la mortalidad. La mediana de supervivencia global fue de 52 meses, 47 meses con sacrectom&#xed;a y 73 meses sin sacrectom&#xed;a ( p = 0,059). Las puntuaciones de calidad de vida no fueron significativamente diferentes entre las puntuaciones del componente f&#xed;sico ( p = 0,346), componente mental ( p = 0,787) o la evaluaci&#xf3;n funcional de la terapia contra el c&#xe1;ncer - colorrectal ( p = 0,679) a los 24 meses de seguimiento.LIMITACIONES:La generalizaci&#xf3;n de estos hallazgos puede estar limitada fuera de las unidades de exenteraci&#xf3;n de subespecialistas. Existe un sesgo de selecci&#xf3;n en un an&#xe1;lisis retrospectivo.CONCLUSIONES:Los pacientes sometidos a exenteraci&#xf3;n p&#xe9;lvica con y sin sacrectom&#xed;a en bloque por c&#xe1;ncer de recto con recurrencia local experimentan tasas similares de resecci&#xf3;n R0, supervivencia y resultados de calidad de vida. Como R0 sigue siendo el predictor m&#xe1;s importante de supervivencia, la necesidad de resecci&#xf3;n sacra debe provocar la derivaci&#xf3;n a un centro subespecialista que realice sacrectom&#xed;a de forma rutinaria. (Traducci&#xf3;n-Dr. Fidel Ruiz Healy ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Waller</LastName><ForeName>Jacob H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-1656-8667</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Kessel</LastName><ForeName>Charlotte S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Kirk K S</ForeName><Initials>KKS</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steffens</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010385" MajorTopicYN="Y">Pelvic Exenteration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012447" MajorTopicYN="N">Sacrum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072662" MajorTopicYN="N">Margins of Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>18</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38408876</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003154</ArticleId><ArticleId IdType="pii">00003453-202406000-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Milne T, Solomon MJ, Lee P, et al. Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies. Dis Colon Rectum. 2014;57:1153&#x2013;1161.</Citation></Reference><Reference><Citation>Boyle KM, Sagar PM, Chalmers AG, Sebag-Montefiore D, Cairns A, Eardley I. Surgery for locally recurrent rectal cancer. Dis Colon Rectum. 2005;48:929&#x2013;937.</Citation></Reference><Reference><Citation>Milne T, Solomon MJ, Lee P, Young JM, Stalley P, Harrison JD. Assessing the impact of a sacral resection on morbidity and survival after extended radical surgery for locally recurrent rectal cancer. Ann Surg. 2013;258:1007&#x2013;1013.</Citation></Reference><Reference><Citation>Heriot AG, Byrne CM, Lee P, et al. Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum. 2008;51:284&#x2013;291.</Citation></Reference><Reference><Citation>Wanebo HJ, Antoniuk P, Koness RJ, et al. Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum. 1999;42:1438&#x2013;1448.</Citation></Reference><Reference><Citation>Solomon MJ, Tan K-K, Bromilow RG, Al-mozany N, Lee PJ. Sacrectomy via the abdominal approach during pelvic exenteration. Dis Colon Rectum. 2014;57:272&#x2013;277.</Citation></Reference><Reference><Citation>Rogers AC, Jenkins JT, Rasheed S, et al. Towards standardisation of technique for en bloc sacrectomy for locally advanced and recurrent rectal cancer. J Clin Med. 2021;10:4921.</Citation></Reference><Reference><Citation>Shaikh I, Holloway I, Aston W, et al.; Complex Cancer Clinic St Mark's Hospital London. High subcortical sacrectomy: a novel approach to facilitate complete resection of locally advanced and recurrent rectal cancer with high (S1-S2) sacral extension. Colorectal Dis. 2016;18:386&#x2013;392.</Citation></Reference><Reference><Citation>Lau YC, Jongerius K, Wakeman C, et al. Influence of the level of sacrectomy on survival in patients with locally advanced and recurrent rectal cancer. Br J Surg. 2019;106:484&#x2013;490.</Citation></Reference><Reference><Citation>Khaled F, Smith MJ, Moises C, Smith AJ, Yee AJM. Single-stage anterior high sacrectomy for locally recurrent rectal cancer. Spine. 2014;39:443&#x2013;452.</Citation></Reference><Reference><Citation>Sasikumar A, Bhan C, Jenkins JT, Antoniou A, Murphy J. Systematic review of pelvic exenteration with en bloc sacrectomy for recurrent rectal adenocarcinoma: R0 resection predicts disease-free survival. Dis Colon Rectum. 2017;60:346&#x2013;352.</Citation></Reference><Reference><Citation>McCarthy ASE, Solomon MJ, Koh CE, Firouzbakht A, Jackson SA, Steffens D. Quality of life and functional outcomes following pelvic exenteration and sacrectomy. Colorectal Dis. 2020;22:521&#x2013;528.</Citation></Reference><Reference><Citation>Steffens D, Solomon MJ, Young JM, et al. Cohort study of long-term survival and quality of life following pelvic exenteration: survival and quality of life after pelvic exenteration. BJS Open. 2018;2:328&#x2013;335.</Citation></Reference><Reference><Citation>Brown KGM, Solomon MJ, Lau YC, Steffens D, Austin KKS, Lee PJ. Sciatic and femoral nerve resection during extended radical surgery for advanced pelvic tumours: long-term survival, functional, and quality-of-life outcomes. Ann Surg. 2021;273:982&#x2013;988.</Citation></Reference><Reference><Citation>van Kessel CS, Solomon MJ. Understanding the philosophy, anatomy, and surgery of the extra-TME plane of locally advanced and locally recurrent rectal cancer; single institution experience with international benchmarking. Cancers (Basel). 2022;14:5058.</Citation></Reference><Reference><Citation>Koh CE, Brown KGM, Steffens D, Young J, Salkeld G, Solomon MJ. What constitutes a clear margin in patients with locally recurrent rectal cancer undergoing pelvic exenteration? Ann Surg. 2022;275:157&#x2013;165.</Citation></Reference><Reference><Citation>Brown KGM, Solomon MJ. Decision making, treatment planning and technical considerations in patients undergoing surgery for locally recurrent rectal cancer. Semin Colon Rectal Surg. 2020;31:100764.</Citation></Reference><Reference><Citation>Evans MD, Harji DP, Sagar PM, et al. Partial anterior sacrectomy with nerve preservation to treat locally advanced rectal cancer. Colorectal Dis. 2013;15:e336&#x2013;e339.</Citation></Reference><Reference><Citation>van Ramshorst GH, Young JM, Solomon MJ. Complications and impact on quality of life of vertical rectus abdominis myocutaneous flaps for reconstruction in pelvic exenteration surgery. Dis Colon Rectum. 2020;63:1225&#x2013;1233.</Citation></Reference><Reference><Citation>Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473&#x2013;483.</Citation></Reference><Reference><Citation>Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res. 1999;8:181&#x2013;195.</Citation></Reference><Reference><Citation>PelvEx Collaborative. Contemporary management of locally advanced and recurrent rectal cancer: views from the PelvEx Collaborative. Cancers (Basel). 2022;14:1161.</Citation></Reference><Reference><Citation>Harris CA, Solomon MJ, Heriot AG, et al. The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg. 2016;264:323&#x2013;329.</Citation></Reference><Reference><Citation>Kelly ME, Glynn R, Aalbers AGJ, et al. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg. 2018;105:650&#x2013;657.</Citation></Reference><Reference><Citation>Madoff RD. Extended resections for advanced rectal cancer. Br J Surg. 2006;93:1311&#x2013;1312.</Citation></Reference><Reference><Citation>Denost Q, Solomon M, Tuech JJ, et al. International variation in managing locally advanced or recurrent rectal cancer: prospective benchmark analysis. Br J Surg. 2020;107:1846&#x2013;1854.</Citation></Reference><Reference><Citation>Palmer G, Martling A, Cedermark B, Holm T. A population-based study on the management and outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2007;14:447&#x2013;454.</Citation></Reference><Reference><Citation>Sagar PM, Gonsalves S, Heath RM, Phillips N, Chalmers AG. Composite abdominosacral resection for recurrent rectal cancer. Br J Surg. 2009;96:191&#x2013;196.</Citation></Reference><Reference><Citation>Melton GB, Paty PB, Boland PJ, et al. Sacral resection for recurrent rectal cancer: analysis of morbidity and treatment results. Dis Colon Rectum. 2006;49:1099&#x2013;1107.</Citation></Reference><Reference><Citation>Austin KKS, Young JM, Solomon MJ. Quality of life of survivors after pelvic exenteration for rectal cancer. Dis Colon Rectum. 2010;53:1121&#x2013;1126.</Citation></Reference><Reference><Citation>Waller J, van Kessel C, Lee P, Austin K, Steffens D, Solomon M. Outcomes following pelvic exenteration with en bloc sacrectomy for recurrent rectal cancer. [ASCRS Abstract M8]. Dis Colon Rectum. 2023;66:e377.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37493254</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Pelvic Exenteration for Squamous Cell Carcinoma of the Anus: Oncological, Morbidity, and Quality-of-Life Outcomes.</ArticleTitle><Pagination><StartPage>1427</StartPage><EndPage>1434</EndPage><MedlinePgn>1427-1434</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002919</ELocationID><Abstract><AbstractText Label="BACKGROUND">Salvage surgery is the only potentially curative treatment option for recurrent squamous cell carcinoma of the anus. Where adjacent pelvic viscera, soft tissues, and bone are involved, pelvic exenteration with a wide perineal excision may be required to ensure clear surgical margins and increase the likelihood of long-term survival.</AbstractText><AbstractText Label="OBJECTIVE">To report oncological, morbidity, and quality-of-life outcomes of pelvic exenteration for anal squamous cell carcinoma.</AbstractText><AbstractText Label="DESIGN">Cohort study with retrospective analysis of prospectively collected data.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a high-volume pelvic exenteration center.</AbstractText><AbstractText Label="PATIENTS">Those who underwent pelvic exenteration for anal squamous cell carcinoma between 1994 and 2022.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Local recurrence-free and overall survival, intraoperative and postoperative complication rates, R0 resection rate, and long-term quality-of-life outcomes.</AbstractText><AbstractText Label="RESULTS">Of 958 patients who underwent pelvic exenteration, 66 (6.9%) had anal squamous cell carcinoma. Thirty-two patients (48.5%) were male and the median age was 57 years (range, 31-79). Ten patients (15%) had primary anal squamous cell carcinoma, 49 (74%) had a recurrent tumor, and 7 (11%) had a re-recurrent tumor. Twenty-two patients (33%) and 16 patients (24%) had a major complication and unplanned return to the operating theater, respectively. Of the 62 patients who underwent pelvic exenteration with curative intent, 50 (81%) had R0 resection, and the 5-year overall and local recurrence-free survival rates were 41% and 37%, respectively. R0 resection was associated with a higher 5-year overall survival (50% vs 8%, p &lt; 0.001). The mental health component scores and several individual quality-of-life domains presented improved trajectories postoperatively (all p values &lt;0.05).</AbstractText><AbstractText Label="LIMITATIONS">The generalizability of the findings outside specialist pelvic exenteration centers may be limited.</AbstractText><AbstractText Label="CONCLUSIONS">Morbidity, long-term survival, and quality-of-life outcomes after pelvic exenteration for anal squamous cell carcinoma are comparable to published outcomes of pelvic exenteration for other tumor types.</AbstractText><AbstractText Label="EXENTERACIN PLVICA POR CARCINOMA EPIDERMOIDE DE ANO RESULTADOS ONCOLGICOS, DE MORBILIDAD Y DE CALIDAD DE VIDA">ANTECEDENTES:La cirug&#xed;a de rescate es la &#xfa;nica opci&#xf3;n de tratamiento potencialmente curativa para el carcinoma de c&#xe9;lulas escamosas del ano recurrente. Cuando est&#xe1;n involucradas v&#xed;sceras p&#xe9;lvicas, tejidos blandos y huesos adyacentes, puede ser necesaria una exenteraci&#xf3;n p&#xe9;lvica con una escisi&#xf3;n perineal amplia para asegurar m&#xe1;rgenes quir&#xfa;rgicos claros y aumentar la probabilidad de supervivencia a largo plazo.OBJETIVO:Informar sobre los resultados oncol&#xf3;gicos, de morbilidad y de calidad de vida de la exenteraci&#xf3;n p&#xe9;lvica por carcinoma anal de c&#xe9;lulas escamosas.DISE&#xd1;O:Estudio de cohortes con an&#xe1;lisis retrospectivo de datos recogidos prospectivamente.ENTORNO CLINICO:Este estudio se realiz&#xf3; en un centro de exenteraci&#xf3;n p&#xe9;lvica de alto volumen.PACIENTES:Aquellos que se sometieron a exenteraci&#xf3;n p&#xe9;lvica por carcinoma anal de c&#xe9;lulas escamosas entre 1994 y 2022.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:Supervivencia global y libre de recidiva local, tasas de complicaciones intraoperatorias y posoperatorias, tasa de resecci&#xf3;n R0 y resultados de calidad de vida a largo plazo.RESULTADOS:De 958 pacientes que se sometieron a exenteraci&#xf3;n p&#xe9;lvica, 66 (6,9%) ten&#xed;an carcinoma anal de c&#xe9;lulas escamosas. 32 pacientes (48,5%) eran varones y la mediana de edad fue de 57 a&#xf1;os (rango 31-79). 10 pacientes (15%) ten&#xed;an carcinoma anal primario de c&#xe9;lulas escamosas, 49 (74%) ten&#xed;an un tumor recurrente y 7 (11%) ten&#xed;an una segunda recurrencia. 22 (33%) y 16 pacientes (24%) tuvieron una complicaci&#xf3;n mayor y regreso no planificado al quir&#xf3;fano, respectivamente. De los 62 pacientes que se sometieron a una exenteraci&#xf3;n p&#xe9;lvica con intenci&#xf3;n curativa, 50 (81%) tuvieron una resecci&#xf3;n R0, las tasas de supervivencia global y libre de recidiva local a los 5 a&#xf1;os fueron del 41% y el 37%, respectivamente. La resecci&#xf3;n R0 se asoci&#xf3; con una mayor supervivencia general a los 5 a&#xf1;os (50% frente a 8%, p &lt; 0,001). Las puntuaciones del componente de salud mental y varios dominios de calidad de vida individuales presentaron trayectorias mejoradas despu&#xe9;s de la operaci&#xf3;n (todos los valores de p &lt; 0,05).LIMITACIONES:La generalizaci&#xf3;n de los hallazgos fuera de los centros especializados en exenteraci&#xf3;n p&#xe9;lvica puede ser limitada.CONCLUSIONES:Los resultados de morbilidad, supervivencia a largo plazo y calidad de vida despu&#xe9;s de la EP para el carcinoma anal de c&#xe9;lulas escamosas son comparables a los resultados publicados de la exenteraci&#xf3;n p&#xe9;lvica para otros tipos de tumores. (Traducci&#xf3;n-Dr. Ingrid Melo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Kilian G M</ForeName><Initials>KGM</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Central Clinical School, The University of Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Central Clinical School, The University of Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steffens</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Central Clinical School, The University of Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Kheng-Seong</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Central Clinical School, The University of Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Concord Repatriation General Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Kirk K S</ForeName><Initials>KKS</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010385" MajorTopicYN="Y">Pelvic Exenteration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="Y">Anus Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>8</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37493254</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002919</ArticleId><ArticleId IdType="pii">00003453-202311000-00007</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Guren MG, Aagnes B, Nygard M, Dahl O, Moller B. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin Colorectal Cancer. 2019;18:e96&#x2013;e103.</Citation></Reference><Reference><Citation>Deshmukh AA, Suk R, Shiels MS, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001-2015. J Natl Cancer Inst. 2020;112:829&#x2013;838.</Citation></Reference><Reference><Citation>Soeberg MJ, Rogers K, Currow DC, Young JM. Trends in incidence and survival for anal cancer in New South Wales, Australia, 1972-2009. Cancer Epidemiol. 2015;39:842&#x2013;847.</Citation></Reference><Reference><Citation>Lim F, Glynne-Jones R. Chemotherapy/chemoradiation in anal cancer: a systematic review. Cancer Treat Rev. 2011;37:520&#x2013;532.</Citation></Reference><Reference><Citation>Park IJ, Chang G. Survival and operative outcomes after salvage surgery for recurrent or persistent anal cancer. Ann Coloproctol. 2020;36:361&#x2013;373.</Citation></Reference><Reference><Citation>Ko G, Sarkaria A, Merchant SJ, Booth CM, Patel SV. A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer. Colorectal Dis. 2019;21:632&#x2013;650.</Citation></Reference><Reference><Citation>Smith N, Waters PS, Peacock O, et al. Pelvic exenteration for anal and urogenital squamous cell carcinoma: experience and outcomes from an exenteration unit over 12 years. Ann Surg Oncol. 2020;27:2450&#x2013;2456.</Citation></Reference><Reference><Citation>Tan KK, Pal S, Lee PJ, Rodwell L, Solomon MJ. Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca&#x2014;a single institution&#x2019;s experience over 16 years. Colorectal Dis. 2013;15:1227&#x2013;1231.</Citation></Reference><Reference><Citation>Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780&#x2013;2789.</Citation></Reference><Reference><Citation>PelvExCollaborative. Pelvic exenteration for advanced nonrectal pelvic malignancy. Ann Surg. 2019;270:899&#x2013;905.</Citation></Reference><Reference><Citation>Brown KGM, Solomon MJ. Decision making, treatment planning and technical considerations in patients undergoing surgery for locally recurrent rectal cancer. Semin Colon Rectal Surg. 2020;31:100764.</Citation></Reference><Reference><Citation>Chang KH, Solomon MJ. The role of surgery in the palliation of advanced pelvic malignancy. Eur J Surg Oncol. 2022;48:2323&#x2013;2329.</Citation></Reference><Reference><Citation>Solomon MJ, Brown KGM. Extended radical resection: the standard of care for patients with advanced pelvic malignancy. Ann Surg Oncol. 2020;27:323&#x2013;324.</Citation></Reference><Reference><Citation>Solomon MJ, Alahmadi R, Lee PJ, Austin KKS. En bloc partial pubic bone excision with complete soft tissue pelvic exenteration. Br J Surg. 2022;109:640&#x2013;641.</Citation></Reference><Reference><Citation>Solomon MJ, Tan KK, Bromilow RG, Al-mozany N, Lee PJ. Sacrectomy via the abdominal approach during pelvic exenteration. Dis Colon Rectum. 2014;57:272&#x2013;277.</Citation></Reference><Reference><Citation>Austin KK, Solomon MJ. Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement. Dis Colon Rectum. 2009;52:1223&#x2013;1233.</Citation></Reference><Reference><Citation>Solomon MJ, Daster S, Loizides S, et al. Access to the anterior pelvic compartment in pelvic exenteration in women&#x2014;the interlabial approach: video vignette. Br J Surg. 2021;108:e268&#x2013;e269.</Citation></Reference><Reference><Citation>Witte DYS, van Ramshorst GH, Lapid O, Bouman MB, Tuynman JB. Flap reconstruction of perineal defects after pelvic exenteration: a systematic description of four choices of surgical reconstruction methods. Plast Reconstr Surg. 2021;147:1420&#x2013;1435.</Citation></Reference><Reference><Citation>Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187&#x2013;196.</Citation></Reference><Reference><Citation>Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473&#x2013;483.</Citation></Reference><Reference><Citation>Brown KGM, Solomon MJ. Exenterative surgery for squamous cell carcinoma arising from pelvic organs of cloacal origin. Ann Surg Oncol. 2020;27:2135&#x2013;2136.</Citation></Reference><Reference><Citation>Correa JH, Castro LS, Kesley R, et al. Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival. J Surg Oncol. 2013;107:486&#x2013;492.</Citation></Reference><Reference><Citation>Lefevre JH, Corte H, Tiret E, et al. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol. 2012;19:4186&#x2013;4192.</Citation></Reference><Reference><Citation>Hallemeier CL, You YN, Larson DW, et al. Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Dis Colon Rectum. 2014;57:442&#x2013;448.</Citation></Reference><Reference><Citation>Wright JL, Gollub MJ, Weiser MR, et al. Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous cell carcinoma of the anal canal. Dis Colon Rectum. 2011;54:1090&#x2013;1097.</Citation></Reference><Reference><Citation>Khaw CW, Ebrahimi N, Lee P, McCarthy ASE, Solomon M. Long-term results of mesh pelvic floor reconstruction to address the empty pelvis syndrome. Colorectal Dis. 2022;24:1211&#x2013;1215.</Citation></Reference><Reference><Citation>Sutton PA, Brown KGM, Ebrahimi N, Solomon MJ, Austin KKS, Lee PJ. Long-term surgical complications following pelvic exenteration: operative management of the empty pelvis syndrome. Colorectal Dis. 2022;24:1491&#x2013;1497.</Citation></Reference><Reference><Citation>Johnson YL, West MA, Gould LE, et al. Empty pelvis syndrome: a systematic review of reconstruction techniques and their associated complications. Colorectal Dis. 2021;24:16&#x2013;26.</Citation></Reference><Reference><Citation>Bankar S, Desouza A, Paliwal V, et al. Novel use of the Bakri balloon to minimize empty pelvis syndrome following laparoscopic total pelvic exenteration. Colorectal Dis. 2020;22:2322&#x2013;2325.</Citation></Reference><Reference><Citation>Steffens D, Solomon MJ, Young JM, et al. Cohort study of long-term survival and quality of life following pelvic exenteration. BJS Open. 2018;2:328&#x2013;335.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36649145</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Comparison of Robotic, Laparoscopic, and Open Resections of Nonmetastatic Colon Cancer.</ArticleTitle><Pagination><StartPage>1347</StartPage><EndPage>1358</EndPage><MedlinePgn>1347-1358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002637</ELocationID><Abstract><AbstractText Label="BACKGROUND">Laparoscopic resection for colon cancer has not been associated with improvements in oncological outcomes in comparison to open resection. Robotic resections are associated with increased lymph node yield and radicality of mesenteric resection in patients with right-sided tumors. It is unclear whether lymph node yield is higher in robotic resections in other parts of the colon and whether higher lymph node yield is associated with improved survival.</AbstractText><AbstractText Label="OBJECTIVE">To compare survival rates between robotic, laparoscopic, and open resections in a large cohort of patients with nonmetastatic colon cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective observational study.</AbstractText><AbstractText Label="SETTING">A single comprehensive cancer center.</AbstractText><AbstractText Label="PATIENTS">Patients who underwent resection of nonmetastatic primary colon cancer between January 2006 and December 2018.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Univariable and multivariable models were used to identify predictors of disease-free and overall survival. Lymph node yield and perioperative outcomes were compared between operative approaches.</AbstractText><AbstractText Label="RESULTS">There were 2398 patients who met the inclusion criteria: 699 (29%) underwent open, 824 (34%) underwent laparoscopic, and 875 (36%) underwent robotic resection. The median follow-up was 3.8 years (45.4 months). Robotic surgery was associated with higher lymph node yield and radicality of mesenteric resection. On multivariable analysis, the surgical approach was not associated with a difference in disease-free or overall survival. Minimally invasive colectomy was associated with fewer complications and shorter length of stay in comparison to open surgery. In a direct comparison between the 2 minimally invasive approaches, robotic colectomy was associated with fewer complications, shorter length of stay, and lower conversion rate than laparoscopy.</AbstractText><AbstractText Label="LIMITATIONS">This was a single-center retrospective study.</AbstractText><AbstractText Label="CONCLUSIONS">Our data indicate that the 3 surgical approaches are similarly effective in treating primary resectable colon cancer and that differences in outcomes are observed primarily in the early postoperative period. See Video Abstract at http://links.lww.com/DCR/C115 .</AbstractText><AbstractText Label="COMPARACIN DE RESECCIONES ROBTICAS, LAPAROSCPICAS Y ABIERTAS DE CNCER DE COLON NO METASTSICO">ANTECEDENTES:La resecci&#xf3;n laparosc&#xf3;pica para el c&#xe1;ncer de colon no se ha asociado con mejoras en los resultados oncol&#xf3;gicos en comparaci&#xf3;n con la resecci&#xf3;n abierta. Las resecciones rob&#xf3;ticas se asocian con un mayor rendimiento de los ganglios linf&#xe1;ticos y la radicalidad de la resecci&#xf3;n mesent&#xe9;rica en pacientes con tumores del lado derecho. No est&#xe1; claro si la cosecha ganglionar es mayor en las resecciones rob&#xf3;ticas en otras partes del colon y si un mayor rendimiento de los ganglios linf&#xe1;ticos se asocia con una mejor supervivencia.OBJETIVO:Comparar las tasas de supervivencia entre resecciones rob&#xf3;ticas, laparosc&#xf3;picas y abiertas en una gran cohorte de pacientes con c&#xe1;ncer de colon no metast&#xe1;sico.DISE&#xd1;O:Este es un estudio observacional retrospectivo.ESCENARIO:Este estudio se realiz&#xf3; en un &#xfa;nico centro oncol&#xf3;gico integral.PACIENTES:Pacientes que se sometieron a resecci&#xf3;n de c&#xe1;ncer de colon primario no metast&#xe1;sico entre enero de 2006 y diciembre de 2018.PRINCIPALES MEDIDAS DE RESULTADO:Se utilizaron modelos univariables y multivariables para identificar predictores de supervivencia libre de enfermedad y global. La cosecha ganglionar y los resultados perioperatorios se compararon entre los abordajes quir&#xfa;rgicos.RESULTADOS:Hubo 2398 pacientes que cumplieron con los criterios de inclusi&#xf3;n: 699 (29%) se sometieron a cirug&#xed;a abierta, 824 (34%) se sometieron a resecci&#xf3;n laparosc&#xf3;pica y 875 (36%) se sometieron a resecci&#xf3;n rob&#xf3;tica. La mediana de seguimiento fue de 3,8 a&#xf1;os (45,4 meses). La cirug&#xed;a rob&#xf3;tica se asoci&#xf3; con una mayor cosecha ganglionar y la radicalidad de la resecci&#xf3;n mesent&#xe9;rica. En el an&#xe1;lisis multivariable, el abordaje quir&#xfa;rgico no se asoci&#xf3; con una diferencia en la supervivencia general o libre de enfermedad. La colectom&#xed;a m&#xed;nimamente invasiva se asoci&#xf3; con menos complicaciones y una estancia m&#xe1;s corta en comparaci&#xf3;n con la cirug&#xed;a abierta. En una comparaci&#xf3;n directa entre los dos enfoques m&#xed;nimamente invasivos, la colectom&#xed;a rob&#xf3;tica se asoci&#xf3; con menos complicaciones, una estancia m&#xe1;s corta y una tasa de conversi&#xf3;n m&#xe1;s baja que la laparoscopia.LIMITACIONES:Este fue un estudio retrospectivo de un solo centro.CONCLUSIONES:Nuestros datos indican que los tres enfoques quir&#xfa;rgicos son igualmente efectivos en el tratamiento del c&#xe1;ncer de colon resecable primario y que las diferencias en los resultados se observan principalmente en el per&#xed;odo posoperatorio temprano. Consulte Video Resumen en http://links.lww.com/DCR/C115 . (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuval</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tel Aviv Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Hannah M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verheij</LastName><ForeName>Floris S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiasconaro</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tel Aviv Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Sujata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tel Aviv Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widmar</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Iris H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappou</LastName><ForeName>Emmanouil P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jesse J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nash</LastName><ForeName>Garrett M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiser</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paty</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Aguilar</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009501</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="Y">Robotic Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">La resecci&#xf3;n laparosc&#xf3;pica para el c&#xe1;ncer de colon no se ha asociado con mejoras en los resultados oncol&#xf3;gicos en comparaci&#xf3;n con la resecci&#xf3;n abierta. Las resecciones rob&#xf3;ticas se asocian con un mayor rendimiento de los ganglios linf&#xe1;ticos y la radicalidad de la resecci&#xf3;n mesent&#xe9;rica en pacientes con tumores del lado derecho. No est&#xe1; claro si el rendimiento de los ganglios linf&#xe1;ticos es mayor en las resecciones rob&#xf3;ticas en otras partes del colon y si un mayor rendimiento de los ganglios linf&#xe1;ticos se asocia con una mejor supervivencia.</AbstractText><AbstractText Label="OBJETIVO:">Comparar las tasas de supervivencia entre resecciones rob&#xf3;ticas, laparosc&#xf3;picas y abiertas en una gran cohorte de pacientes con c&#xe1;ncer de colon no metast&#xe1;sico.</AbstractText><AbstractText Label="DISE&#xd1;O:">Este es un estudio observacional retrospectivo.</AbstractText><AbstractText Label="AJUSTE:">Este estudio se realiz&#xf3; en un &#xfa;nico centro oncol&#xf3;gico integral.</AbstractText><AbstractText Label="PACIENTES:">Pacientes que se sometieron a resecci&#xf3;n de c&#xe1;ncer de colon primario no metast&#xe1;sico entre enero de 2006 y diciembre de 2018.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADO:">Se utilizaron modelos univariables y multivariables para identificar predictores de supervivencia libre de enfermedad y global. El rendimiento de los ganglios linf&#xe1;ticos y los resultados perioperatorios se compararon entre los enfoques operativos.</AbstractText><AbstractText Label="RESULTADOS:">Hubo 2398 pacientes que cumplieron con los criterios de inclusi&#xf3;n: 699 (29%) se sometieron a cirug&#xed;a abierta, 824 (34%) se sometieron a resecci&#xf3;n laparosc&#xf3;pica y 875 (36%) se sometieron a resecci&#xf3;n rob&#xf3;tica. La mediana de seguimiento fue de 3,8 a&#xf1;os (45,4 meses). La cirug&#xed;a rob&#xf3;tica se asoci&#xf3; con un mayor rendimiento de los ganglios linf&#xe1;ticos y la radicalidad de la resecci&#xf3;n mesent&#xe9;rica. En el an&#xe1;lisis multivariable, el abordaje quir&#xfa;rgico no se asoci&#xf3; con una diferencia en la supervivencia general o libre de enfermedad. La colectom&#xed;a m&#xed;nimamente invasiva se asoci&#xf3; con menos complicaciones y una estancia m&#xe1;s corta en comparaci&#xf3;n con la cirug&#xed;a abierta. En una comparaci&#xf3;n directa entre los dos enfoques m&#xed;nimamente invasivos, la colectom&#xed;a rob&#xf3;tica se asoci&#xf3; con menos complicaciones, una estancia m&#xe1;s corta y una tasa de conversi&#xf3;n m&#xe1;s baja que la laparoscopia.</AbstractText><AbstractText Label="LIMITACIONES:">Este fue un estudio retrospectivo de un solo centro.</AbstractText><AbstractText Label="CONCLUSIONES:">Nuestros datos indican que los tres enfoques quir&#xfa;rgicos son igualmente efectivos en el tratamiento del c&#xe1;ncer de colon resecable primario y que las diferencias en los resultados se observan principalmente en el per&#xed;odo posoperatorio temprano. Consulte Video Resumen en http://links.lww.com/DCR/Bxxx. <i>(Pre-proofed version)</i></AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36649145</ArticleId><ArticleId IdType="mid">NIHMS1914333</ArticleId><ArticleId IdType="pmc">PMC10369538</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002637</ArticleId><ArticleId IdType="pii">00003453-202310000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lacy AM, Garc&#xed;a-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224&#x2013;2229.</Citation><ArticleIdList><ArticleId IdType="pubmed">12103285</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson H, Sargent DJ, Wieand HS, et al.; Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pubmed">15141043</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillou PJ, Quirke P, Thorpe H, et al.; MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365:1718&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15894098</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldkamp R, Kuhry E, Hop WC, et al.; COlon cancer Laparoscopic or Open Resection Study Group (COLOR). Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005;6:477&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewett PJ, Allardyce RA, Bagshaw PF, et al. Short-term outcomes of the Australasian randomized clinical study comparing laparoscopic and conventional open surgical treatments for colon cancer: the ALCCaS trial. Ann Surg. 2008;248:728&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">18948799</ArticleId></ArticleIdList></Reference><Reference><Citation>Buunen M, Veldkamp R, Hop WC, et al.; Colon Cancer Laparoscopic or Open Resection Study Group. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 2009;10:44&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">19071061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagshaw PF, Allardyce RA, Frampton CM, et al.; Australasian Laparoscopic Colon Cancer Study Group. Long-term outcomes of the australasian randomized clinical trial comparing laparoscopic and conventional open surgical treatments for colon cancer: the Australasian Laparoscopic Colon Cancer Study trial. Ann Surg. 2012;256:915&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">23154392</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne DG, Guillou PJ, Thorpe H, et al.; UK MRC CLASICC Trial Group. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061&#x2013;3068.</Citation><ArticleIdList><ArticleId IdType="pubmed">17634484</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Kang H, Park SY, et al. Long-term oncologic after robotic versus laparoscopic right colectomy: a prospective randomized study. Surg Endosc. 2019;33:2975&#x2013;2981.</Citation><ArticleIdList><ArticleId IdType="pubmed">30456502</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Zhao Z, Jia B, Liu R, Liu H. Perioperative and long-term outcomes of robot-assisted versus laparoscopy-assisted hemicolectomy for left-sided colon cancers: a retrospective study. Updates Surg. 2021;73:1049&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184556</ArticleId><ArticleId IdType="pubmed">33394355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinar I, Fransgaard T, Thygesen LC, G&#xf6;genur I. Long-term outcomes of robot-assisted surgery in patients with colorectal cancer. Ann Surg Oncol. 2018;25:3906&#x2013;3912.</Citation><ArticleIdList><ArticleId IdType="pubmed">30311167</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinoglio G, Bianchi PP, Marano A, et al. Robotic versus laparoscopic right colectomy with complete mesocolic excision for the treatment of colon cancer: perioperative outcomes and 5-year survival in a consecutive series of 202 patients. Ann Surg Oncol. 2018;25:3580&#x2013;3586.</Citation><ArticleIdList><ArticleId IdType="pubmed">30218248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirkin KA, Kulaylat AS, Hollenbeak CS, Messaris E. Robotic versus laparoscopic colectomy for stage I-III colon cancer: oncologic and long-term survival outcomes. Surg Endosc. 2018;32:2894&#x2013;2901.</Citation><ArticleIdList><ArticleId IdType="pubmed">29273877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Park YA, Baik SH, Sohn SK, Lee KY. A comparison of open, laparoscopic, and robotic surgery in the treatment of right-sided colon cancer. Surg Laparosc Endosc Percutan Tech. 2016;26:497&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">27846182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ow ZGW, Sim W, Nistala KRY, et al. Comparing complete mesocolic excision versus conventional colectomy for colon cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2021;47:732&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">32951936</ArticleId></ArticleIdList></Reference><Reference><Citation>Killeen S, Mannion M, Devaney A, Winter DC. Complete mesocolic resection and extended lymphadenectomy for colon cancer: a systematic review. Colorectal Dis. 2014;16:577&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">24655722</ArticleId></ArticleIdList></Reference><Reference><Citation>Widmar M, Keskin M, Strombom P, et al. Lymph node yield in right colectomy for cancer: a comparison of open, laparoscopic and robotic approaches. Colorectal Dis. 2017;19:888&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642033</ArticleId><ArticleId IdType="pubmed">28649796</ArticleId></ArticleIdList></Reference><Reference><Citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360123</ArticleId><ArticleId IdType="pubmed">15273542</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufts LS, Jarnagin ED, Flynn JR, et al. A perioperative multidisciplinary care bundle reduces surgical site infections in patients undergoing synchronous colorectal and liver resection. HPB (Oxford). 2019;21:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358518</ArticleId><ArticleId IdType="pubmed">30077525</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei IH, Pappou EP, Smith JJ, et al. Monitoring an ongoing enhanced recovery after surgery (ERAS) program: adherence improves clinical outcomes in a comparison of three thousand colorectal cases. Clin Surg. 2020;5:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643765</ArticleId><ArticleId IdType="pubmed">33163851</ArticleId></ArticleIdList></Reference><Reference><Citation>Trepanier M, Erkan A, Kouyoumdjian A, et al. Examining the relationship between lymph node harvest and survival in patients undergoing colectomy for colon adenocarcinoma. Surgery. 2019;166:639&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">31399220</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleshman J, Sargent DJ, Green E, et al.; Clinical Outcomes of Surgical Therapy Study Group. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg. 2007;246:655&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">17893502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM, Guillou PJ. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg. 2010;97:1638&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">20629110</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi T, Shimada Y, Hsu M, et al. Contemporary validation of a nomogram predicting colon cancer recurrence, revealing all-stage improved outcomes. JNCI Cancer Spectr. 2019;3:pkz015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512350</ArticleId><ArticleId IdType="pubmed">31119207</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahani DV, Kalva SP, Fischman AJ, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol. 2005;185:239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15972430</ArticleId></ArticleIdList></Reference><Reference><Citation>Adileh M, Yuval JB, Walch HS, et al. Primary tumor location and outcomes after cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases of colorectal origin. Ann Surg Oncol. 2021;28:1109&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7855731</ArticleId><ArticleId IdType="pubmed">32844293</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9; T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109&#x2013;3116.</Citation><ArticleIdList><ArticleId IdType="pubmed">19451431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ; Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020&#x2013;2029.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee L, Wong-Chong N, Kelly JJ, Nassif GJ, Albert MR, Monson JRT. Minimally invasive surgery for stage III colon adenocarcinoma is associated with less delay to initiation of adjuvant systemic therapy and improved survival. Surg Endosc. 2019;33:460&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29967992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofshteyn A, Bingmer K, Towe CW, Steinhagen E, Stein SL. Robotic proctectomy for rectal cancer in the US: a skewed population. Surg Endosc. 2020;34:2651&#x2013;2656.</Citation><ArticleIdList><ArticleId IdType="pubmed">31372887</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa J, Grass F, Dozois EJ, et al. Robotic surgery for rectal cancer provides advantageous outcomes over laparoscopic approach: results from a large retrospective cohort. Ann Surg. 2021;274:e1218&#x2013;e1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">32068552</ArticleId></ArticleIdList></Reference><Reference><Citation>Simianu VV, Gaertner WB, Kuntz K, et al. Cost-effectiveness evaluation of laparoscopic versus robotic minimally invasive colectomy. Ann Surg. 2020;272:334&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">32675547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary RK, Mullard AJ, Ferraro J, Regenbogen SE. The cost of conversion in robotic and laparoscopic colorectal surgery. Surg Endosc. 2018;32:1515&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7795723</ArticleId><ArticleId IdType="pubmed">28916895</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan JE, Speicher PJ, Thacker JK, Walter M, Kuchibhatla M, Mantyh CR. The preventive surgical site infection bundle in colorectal surgery: an effective approach to surgical site infection reduction and health care cost savings. JAMA Surg. 2014;149:1045&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">25163027</ArticleId></ArticleIdList></Reference><Reference><Citation>Widmar M, Keskin M, Strombom P, et al. Evaluating the validity of the Clavien-Dindo classification in colectomy studies: a 90-day cost of care analysis. Dis Colon Rectum 2021;64:1426&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8502230</ArticleId><ArticleId IdType="pubmed">34623350</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantz O, Zagadailov P, Merchant AM. The cost of surgical site infections after colorectal surgery in the United States from 2001 to 2012: a longitudinal analysis. Am Surg. 2019;85:142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">30819289</ArticleId></ArticleIdList></Reference><Reference><Citation>Justiniano CF, Becerra AZ, Xu Z, et al. A population-based study of 90-day hospital cost and utilization associated with robotic surgery in colon and rectal cancer. J Surg Res. 2020;245:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">31419638</ArticleId></ArticleIdList></Reference><Reference><Citation>den Bakker CM, Anema JR, Huirne JAF, Twisk J, Bonjer HJ, Schaafsma FG. Predicting return to work among patients with colorectal cancer. Br J Surg. 2020;107:140&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6973054</ArticleId><ArticleId IdType="pubmed">31654404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla A, Williams JP, Hurst NG, et al. One-third of patients fail to return to work 1 year after surgery for colorectal cancer. Tech Coloproctol. 2014;18:1153&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">25380740</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf8;rth R, Wong C, Kragholm K, et al. Return to the workforce after first hospitalization for heart failure: a Danish nationwide cohort study. Circulation. 2016;134:999&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">27507406</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37583980</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2708-7212</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Archivos peruanos de cardiologia y cirugia cardiovascular</Title><ISOAbbreviation>Arch Peru Cardiol Cir Cardiovasc</ISOAbbreviation></Journal><ArticleTitle>[Acute cardiovascular complications in a Peruvian population of oncology patients].</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.47487/apcyccv.v3i1.192</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To know the most frequent acute cardiovascular complications in a Peruvian population of oncologic patients.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">Retrospective, descriptive study of oncologic patients treated at Clinica Delgado between January 2014 and December 2019, from which the subgroup with the seven most prevalent cancers at the national level was selected according to information from Globocan 2018. Additionally, we evaluated the epidemiology of patients with cardiovascular complications that conditioned their hospitalization or were detected during this, calculating their cardiovascular risk according to Hermann and SCORE risk scales.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Forty-four patients had complications; 27 (61.4%) were hospitalized due to acute cardiovascular causes. The mean age of this subgroup was 69.88 years (SD 12.77), and 22 (81.5%) were older than 60 years. Fourteen (51.9%) were male. According to the Hermann scale, 33.3% had intermediate-risk and 14.9% had a high or very high risk. According to the SCORE scale, 62.97% had an intermediate-risk and 7.40% high risk. The most common acute cardiovascular complications were deep vein thrombosis and ischemic stroke (66.65%). One patient (3.7%) reported previous cardiovascular disease. Four patients (14.8%) had a fatal outcome during hospitalization. The median length of hospitalization was five days.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We present the cases of acute cardiovascular complications in a population of oncologic patients and their vascular risk according to Hermann and SCORE scales. The most common complications were deep vein thrombosis (48.14%), stroke (18.51%), and myocardial infarction (14.81%).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valenzuela-Rodr&#xed;guez</LastName><ForeName>Germ&#xe1;n</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8595-9549</Identifier><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Cl&#xed;nica Delgado. Lima, Per&#xfa;. Servicio de Medicina Interna Cl&#xed;nica Delgado Lima Per&#xfa;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad San Ignacio de Loyola, Unidad de Revisiones Sistem&#xe1;ticas y Metaan&#xe1;lisis, Gu&#xed;as de Pr&#xe1;ctica Cl&#xed;nica y Evaluaciones Tecnol&#xf3;gicas Sanitarias. Lima, Per&#xfa;. Universidad San Ignacio de Loyola Universidad San Ignacio de Loyola Unidad de Revisiones Sistem&#xe1;ticas y Metaan&#xe1;lisis Gu&#xed;as de Pr&#xe1;ctica Cl&#xed;nica y Evaluaciones Tecnol&#xf3;gicas Sanitarias Lima Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lescano-Alva</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8177-9965</Identifier><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a Posoperatoria, Instituto Nacional Cardiovascular, Lima, Per&#xfa;. Servicio de Cardiolog&#xed;a Posoperatoria Instituto Nacional Cardiovascular Lima Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryce-Alberti</LastName><ForeName>Mayte</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2396-4860</Identifier><AffiliationInfo><Affiliation>Universidad Peruana Cayetano Heredia. Lima, Per&#xfa;. Universidad Peruana Cayetano Heredia Universidad Peruana Cayetano Heredia Lima Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portmann-Baracco</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3489-3751</Identifier><AffiliationInfo><Affiliation>Universidad Peruana Cayetano Heredia. Lima, Per&#xfa;. Universidad Peruana Cayetano Heredia Universidad Peruana Cayetano Heredia Lima Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudencio-Le&#xf3;n</LastName><ForeName>Walter</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-2514-5818</Identifier><AffiliationInfo><Affiliation>Servicio de Epidemiolog&#xed;a, Hospital Nacional Edgardo Rebagliati. Lima, Per&#xfa;. Servicio de Epidemiolog&#xed;a Hospital Nacional Edgardo Rebagliati Lima Per&#xfa;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Complicaciones cardiovasculares agudas en una poblaci&#xf3;n peruana de pacientes oncol&#xf3;gicos.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Peru</Country><MedlineTA>Arch Peru Cardiol Cir Cardiovasc</MedlineTA><NlmUniqueID>9918300982406676</NlmUniqueID><ISSNLinking>2708-7212</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO.">Conocer las complicaciones cardiovasculares agudas m&#xe1;s frecuentes en una poblaci&#xf3;n peruana de pacientes oncol&#xf3;gicos.</AbstractText><AbstractText Label="MATERIALES Y M&#xc9;TODOS.">Estudio retrospectivo, descriptivo de pacientes oncol&#xf3;gicos atendidos en la Cl&#xed;nica Delgado entre enero de 2014 a diciembre de 2019, de los cuales se seleccion&#xf3; el subgrupo con los siete c&#xe1;nceres m&#xe1;s prevalentes a nivel nacional seg&#xfa;n la informaci&#xf3;n de Globocan 2018. Adicionalmente, se evalu&#xf3; la epidemiolog&#xed;a de los pacientes con complicaciones cardiovasculares que condicionaron su hospitalizaci&#xf3;n o que se detectaron en ella, ponder&#xe1;ndose su riesgo cardiovascular seg&#xfa;n las escalas de Hermann y SCORE.</AbstractText><AbstractText Label="RESULTADOS.">Cuarenta y cuatro pacientes tuvieron complicaciones; 27 (61,4%) se hospitalizaron debido a causas cardiovasculares agudas. La edad promedio de este subgrupo fue 69,88 a&#xf1;os (DS 12,77) y 22 (81,5%) fueron mayores de 60 a&#xf1;os. Catorce (51,9%) fueron de sexo masculino. De acuerdo con la escala de Hermann, un 33,3% tuvo un riesgo intermedio y 14,9% un riesgo alto o muy alto. De acuerdo con la escala SCORE, 62,97% tuvieron un riesgo intermedio y un 7,40% un riesgo alto. Las complicaciones cardiovasculares agudas m&#xe1;s comunes fueron trombosis venosa profunda e infarto cerebral isqu&#xe9;mico (66,65%). Un paciente (3,7%) report&#xf3; enfermedad cardiovascular previa. Cuatro pacientes (14,8%) tuvieron una evoluci&#xf3;n fatal durante la hospitalizaci&#xf3;n. El tiempo de hospitalizaci&#xf3;n tuvo una mediana de 5 d&#xed;as (4-10).</AbstractText><AbstractText Label="CONCLUSIONES.">Se presentan los casos de complicaciones cardiovasculares agudas en una poblaci&#xf3;n de pacientes oncol&#xf3;gicos y su riesgo cardiovascular seg&#xfa;n las puntuaciones de Hermann y SCORE. Las complicaciones m&#xe1;s frecuentes fueron la trombosis venosa profunda (48,14%), el infarto cerebral (18,51%) y el infarto de miocardio (14,81%).</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Case reports</Keyword><Keyword MajorTopicYN="N">Heart disease</Keyword><Keyword MajorTopicYN="N">Neoplasms</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword></KeywordList><CoiStatement>Declaraci&#xf3;n de conflictos de inter&#xe9;s: Ninguna</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>16</Day><Hour>3</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37583980</ArticleId><ArticleId IdType="pmc">PMC10424505</ArticleId><ArticleId IdType="doi">10.47487/apcyccv.v3i1.192</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aleman BMP, Moser EC, Nuver J, Suter TM, Maraldo MV, Specht L, et al. Cardiovascular disease after cancer therapy. EJC Suppl. 2014;12(1):18&#x2013;28. doi: 10.1016/j.ejcsup.2014.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcsup.2014.03.002</ArticleId><ArticleId IdType="pmc">PMC4250533</ArticleId><ArticleId IdType="pubmed">26217163</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong J, Yan AT, Cramarossa G, Chan KK. Chemotherapy-induced cardiotoxicity detection, prevention, and management. Can J Cardiol. 2014;30(8):869&#x2013;878. doi: 10.1016/j.cjca.2014.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2014.04.029</ArticleId><ArticleId IdType="pubmed">25064580</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer cardio-oncology. Mayo Clin Proc. 2014;89(9):1287&#x2013;1306. doi: 10.1016/j.mayocp.2014.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2014.05.013</ArticleId><ArticleId IdType="pmc">PMC4258909</ArticleId><ArticleId IdType="pubmed">25192616</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia AM, Mitroi C, Mazon Ramos P, Garcia Sanz R, Virizuela JA, Arenas M, et al. Stratification and management of cardiovascular risk in cancer patients A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC and AECC. Rev Esp Cardiol (Engl Ed) 2021;74(5):438&#x2013;448. doi: 10.1016/j.rec.2020.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2020.11.020</ArticleId><ArticleId IdType="pubmed">33712348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, et al. Cardio-Oncology How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation. 2015;132(23):2248&#x2013;2258. doi: 10.1161/CIRCULATIONAHA.115.010484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.010484</ArticleId><ArticleId IdType="pmc">PMC4863699</ArticleId><ArticleId IdType="pubmed">26644247</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevaidis I. Cardio-oncology A Focus on Cardiotoxicity. Eur Cardiol. 2018;13(1):64&#x2013;69. doi: 10.15420/ecr.2017:17:2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/ecr.2017:17:2</ArticleId><ArticleId IdType="pmc">PMC6159462</ArticleId><ArticleId IdType="pubmed">30310475</ArticleId></ArticleIdList></Reference><Reference><Citation>Campia U, Moslehi JJ, Amiri Kordestani L, Barac A, Beckman JA, Chism DD, et al. Cardio-Oncology Vascular and Metabolic Perspectives. Circulation. 2019;139(13):e579&#x2013;e602. doi: 10.1161/CIR.0000000000000641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000641</ArticleId><ArticleId IdType="pmc">PMC6530491</ArticleId><ArticleId IdType="pubmed">30786722</ArticleId></ArticleIdList></Reference><Reference><Citation>Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163&#x2013;175. doi: 10.1016/j.ijcard.2019.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2019.01.038</ArticleId><ArticleId IdType="pubmed">30661849</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela Rodr&#xed;guez G, Pacheco Mendoza M, Mezones Holgu&#xed;n E. Actualizaci&#xf3;n en Cardio-Oncolog&#xed;a para el m&#xe9;dico onc&#xf3;logo cl&#xed;nico. Carcinos. 2016;6(2):81&#x2013;90.</Citation></Reference><Reference><Citation>Tocchetti CG, Ameri P, De Boer RA, D&#xb4;Alessandra YD, Russo M, Sorriento D. Cardiac dysfunction in cancer patients. Cardiovasc Res. 2020;116(11):1820&#x2013;1834. doi: 10.1093/cvr/cvaa222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa222</ArticleId><ArticleId IdType="pubmed">32683451</ArticleId></ArticleIdList></Reference><Reference><Citation>Suter TM, Ewer MS. Cancer drugs and the heart importance and management. Eur Heart J. 2013;34(15):1102&#x2013;1111. doi: 10.1093/eurheartj/ehs181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs181</ArticleId><ArticleId IdType="pubmed">22789916</ArticleId></ArticleIdList></Reference><Reference><Citation>Akolkar G, Bhullar N, Bews H, Shaikh B, Premecz S, Bordun KA, et al. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity. Cardiovasc Ultrasound. 2015;13:18&#x2013;18. doi: 10.1186/s12947-015-0011-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12947-015-0011-x</ArticleId><ArticleId IdType="pmc">PMC4393607</ArticleId><ArticleId IdType="pubmed">25889218</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenneman CG, Sawyer DB. Cardio-Oncology An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res. 2016;118(6):1008&#x2013;1020. doi: 10.1161/CIRCRESAHA.115.303633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.303633</ArticleId><ArticleId IdType="pubmed">26987914</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnano LC, Mart&#xed;nez Cibrian N, Andrade Gonz&#xe1;lez X, Bosch X. Cardiac complications of chemotherapy role of prevention. Curr Treat Options Cardiovasc Med. 2014;16(6):312&#x2013;312. doi: 10.1007/s11936-014-0312-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11936-014-0312-7</ArticleId><ArticleId IdType="pubmed">24817319</ArticleId></ArticleIdList></Reference><Reference><Citation>Asnani A. Cardiotoxicity of Immunotherapy Incidence, Diagnosis, and Management. Curr Oncol Rep. 2018;20(6):44&#x2013;44. doi: 10.1007/s11912-018-0690-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-018-0690-1</ArticleId><ArticleId IdType="pubmed">29644505</ArticleId></ArticleIdList></Reference><Reference><Citation>Coumbe BGT, Groarke JD. Cardiovascular Autonomic Dysfunction in Patients with Cancer. Curr Cardiol Rep. 2018;20(8):69&#x2013;69. doi: 10.1007/s11886-018-1010-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-018-1010-y</ArticleId><ArticleId IdType="pubmed">29971575</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamargo J, Caballero R, Delp&#xf3;n E. Cancer Chemotherapy and Cardiac Arrythmias a Review. Drug Saf. 2015;38(2):129&#x2013;152. doi: 10.1007/s40264-014-0258-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0258-4</ArticleId><ArticleId IdType="pubmed">25577497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease Eur Heart J. Acute Cardiovasc Care. 2021;10(8):947&#x2013;959. doi: 10.1093/ehjacc/zuab056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuab056</ArticleId><ArticleId IdType="pubmed">34453829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz Mori E, Ayala Bustamante L, Burgos-Bustamante J, Pacheco-Rom&#xe1;n C. Cardiotoxicidad por quimioterapia en el Instituto Nacional de Enfermedades Neopl&#xe1;sicas 2012-2016. Horiz Med. 2017;17(3):24&#x2013;28.</Citation></Reference><Reference><Citation>Salinas-Arce J, Valenzuela G, Gonzales A, Salinas E, Granados M. Disfunci&#xf3;n severa del nodo sinusal inducida por un inhibidor de la tirosina quinasa. Carcinos. 2019;9(1):14&#x2013;17.</Citation></Reference><Reference><Citation>De Wall C, Bauersachs J, Berliner D. Cardiooncology-dealing with modern drug treatment long-term complications, and cancer survivorship. Clin Exp Metastasis. 2021;38(4):361&#x2013;371. doi: 10.1007/s10585-021-10106-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10585-021-10106-x</ArticleId><ArticleId IdType="pmc">PMC8318956</ArticleId><ArticleId IdType="pubmed">34117981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945&#x2013;1960. doi: 10.1002/ejhf.1920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1920</ArticleId><ArticleId IdType="pmc">PMC8019326</ArticleId><ArticleId IdType="pubmed">32463967</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretto G, Lazzeroni D, Sartorio CL, Camici PG. Cardiotoxicity in oncology and coronary microcirculation future challenges in theranostics. Front Biosci (Landmark Ed) 2017;22(10):1760&#x2013;1773. doi: 10.2741/4570.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/4570</ArticleId><ArticleId IdType="pubmed">28410144</ArticleId></ArticleIdList></Reference><Reference><Citation>Graffagnino J, Kondapalli L, Arora G, Hawi R, Lenneman CG. Strategies to Prevent Cardiotoxicity. Curr Treat Options Oncol. 2020;21(4):32&#x2013;32. doi: 10.1007/s11864-020-0722-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11864-020-0722-6</ArticleId><ArticleId IdType="pubmed">32270293</ArticleId></ArticleIdList></Reference><Reference><Citation>Seraphim A, Westwood M, Bhuva AN, Crake T, Moon JC, Menezes LJ, et al. Advanced Imaging Modalities to Monitor for Cardiotoxicity. Curr Treat Options Oncol. 2019;20(9):73&#x2013;73. doi: 10.1007/s11864-019-0672-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11864-019-0672-z</ArticleId><ArticleId IdType="pmc">PMC6687672</ArticleId><ArticleId IdType="pubmed">31396720</ArticleId></ArticleIdList></Reference><Reference><Citation>Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021;77(4):392&#x2013;401. doi: 10.1016/j.jacc.2020.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.11.020</ArticleId><ArticleId IdType="pubmed">33220426</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamo CE, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail. 2016;9(2):e002843. doi: 10.1161/CIRCHEARTFAILURE.115.002843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.115.002843</ArticleId><ArticleId IdType="pmc">PMC4743885</ArticleId><ArticleId IdType="pubmed">26839395</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavo N, Raderer M, H&#xfc;lsmann M, Neuhold S, Adlbrecht C, Strunk G, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101(23):1874&#x2013;1880. doi: 10.1136/heartjnl-2015-307848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2015-307848</ArticleId><ArticleId IdType="pubmed">26416836</ArticleId></ArticleIdList></Reference><Reference><Citation>Paredes-Paucar C, L&#xf3;pez-Fern&#xe1;ndez T. Rol del cardi&#xf3;logo en el manejo de pacientes oncol&#xf3;gicos &#xbf;D&#xf3;nde estamos y a d&#xf3;nde debemos ir? Arch Peru Cardiol Cir Cardiovasc. 2021;2(2):103&#x2013;111. doi: 10.47487/apcyccv.v2i2.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.47487/apcyccv.v2i2.140</ArticleId><ArticleId IdType="pmc">PMC10809777</ArticleId><ArticleId IdType="pubmed">38274562</ArticleId></ArticleIdList></Reference><Reference><Citation>Moudgil R, Yeh ET. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents Cardiomyopathy and Beyond. Can J Cardiol. 2016;32(7):863&#x2013;870. doi: 10.1016/j.cjca.2016.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2016.01.027</ArticleId><ArticleId IdType="pmc">PMC4921299</ArticleId><ArticleId IdType="pubmed">27117975</ArticleId></ArticleIdList></Reference><Reference><Citation>Shum K, Solivan A, Parto P, Polin N, Jahangir E. Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic. Ochsner J. 2016;16(3):217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024801</ArticleId><ArticleId IdType="pubmed">27660568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagethon Heck S, Mecinaj A, Hansen Ree A, Hoffmann P, Schulz Menger J, Wang Ferland M, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2x2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021;143(25):2431&#x2013;2440. doi: 10.1161/CIRCULATIONAHA.121.054698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.054698</ArticleId><ArticleId IdType="pmc">PMC8212877</ArticleId><ArticleId IdType="pubmed">33993702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>